Scientific Publications by FDA Staff

Br J Haematol 2007 Dec;139(5):630-4

Chronic lymphocytic leukaemia genetics overview.

Caporaso N, Goldin L, Plass C, Calin G, Marti G, Bauer S, Raveche E, McMaster ML, Ng D, Landgren O, Slager S

Caporaso N (reprint author), Natl Canc Inst, NIH, Div Canc Epidemiol & Genet, Genet Epidemiol Branch, 6120 Execut Blvd, Bethesda, MD 20892 USA Natl Canc Inst, Div Canc Epidemiol & Genet, Genet Epidemiol Branch, Bethesda, MD USA Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol, Human Canc Genet Program, Columbus, OH 43210 USA Ohio State Univ, Immunol & Med Genet & Comprehens Canc Ctr, Dept Mol Virol, Columbus, OH 43210 USA US FDA, Ctr Biol Evaluat & Res, NIH, Div Cell & Gene Therapies,Cellular & Tissue T, Bethesda, MD USA Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Biostat, Rochester, MN USA

Although the familial aspect of chronic lymphocytic leukaemia (CLL) has been appreciated for decades, it is only with the recent confluence of improved molecular and gene technologies and world-wide collaborative networks that accelerated progress has become apparent. In this summary we highlight selected themes in the genetics of CLL emphasizing the opportunities and challenges of this malignancy.